Dadachanji Group has launched Kaisha Pharma, a premier global platform engineered to serve the pharmaceutical and biotechnology sectors worldwide. As a part of a substantial multi-million-euro commitment, the group has already deployed an initial investment of €45 million to accelerate infrastructure, scale, and operational capabilities.

Kaisha Pharma enters the market with a complete tubular glass portfolio—ampoules, vials, prefilled syringes, and cartridges—together with advanced Ready-to-Use (RTU) platforms for vials, prefilled syringes, and cartridges. These solutions are designed to enable safer, faster, and more efficient fill-finish operations while meeting the increasingly stringent expectations of global pharmaceutical manufacturers.

The company is developing a range of specialty containment solutions for high-value biologics, advanced therapeutics, and sensitive drug formulations, where product integrity, compatibility, and performance are critical. By bringing together innovative design, advanced materials science, and deep pharmaceutical expertise, it intends to create packaging solutions for the therapies of tomorrow.

Kairus Dadachanji, Managing Director (MD), Kaisha Pharma, said, “Our previous experience was a defining chapter in our professional journey. Our vision is to create a truly global company that combines entrepreneurial agility, technical excellence, and an unwavering commitment to customer success.”

Kaisha Pharma is strengthened by the capabilities of the other arms of the Dadachanji Group, creating an integrated ecosystem that virtually makes us a one-stop solutions partner for pharmaceutical companies—spanning primary packaging, automation, machinery, fill-finish support systems, and allied pharmaceutical services.

The company’s manufacturing complex will span over 300,000 square feet, with fully integrated state-of-the-art production lines, sophisticated high-end camera inspection systems, and fully equipped laboratories incorporating the latest analytical and testing equipment. These capabilities, combined with robust, time-tested processes and a highly skilled workforce, are designed to deliver consistent, high-quality products—every batch, every time.

Rishad Dadachanji, Director, Kairish Innotech, said, “Over the years, we have earned the trust of customers, partners, and colleagues throughout the pharmaceutical industry. Kaisha Pharma builds upon that foundation while embracing the opportunities of a rapidly evolving global market. We are excited about the future and the value we can create for customers around the world.”

The group is also establishing an International Business Development office in Europe to serve as a hub for customer engagement, technical collaboration, and market development across the region—bringing us closer to our customers and enabling us to respond faster to their evolving requirements.